Business Wire

RAYSUT-CEMENT-COMPANY

17.5.2021 14:01:06 CEST | Business Wire | Press release

Share
Raysut Cement Gets CE, NF Certifications for Conforming to European Standards; Gears up to Export to EU Countries

In a significant endorsement that will support exports to European Union (EU) markets, Oman’s largest cement manufacturer, Raysut Cement Company (RCC), has received CE and NF certifications, two stringent global quality norms validating RCC’s adherence to EU standards in cement production.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005501/en/

The Muscat Stock Market (MSM)-listed RCC said the certifications come at a time when it is expanding exports to newer global markets. Currently, 50 per cent of the company’s output is exported to East Africa, India, Maldives, South Africa, and Indian Ocean islands.

“We consider CE and NF certifications a testimony to our commitment to constantly improve product quality and processes in line with rigorous global safety, quality and environmental regulations,” said Group CEO, Joey Ghose.

The CE (Conformité Européenne) mark, formerly EC mark, is mandatory for selling certain products in the European Economic Area (EEA) since 1985. The NF Mark from AFNOR certification entity is a French compliance norm that ensures product safety, quality, usage ability and performance.

“The certifications fit into our export strategy for newer geographies as the CE Mark that endorses compliance with EU’s health, safety and green regulations allows us to market our products in Iceland, Liechtenstein and Norway,” said Mr. Ghose.

Winning the certifications also coincided with RCC clinching a new export order from the Reunion Islands in the western Indian Ocean, and an annual contract has already been signed with Enterprise Audemard Group of the French island to ship 8,000 MT cement every month. The first shipment has been received by the party. RCC is also looking at setting up a grinding unit in Madagascar to leverage the 7-8 per cent Y-o-Y growth in that country’s market.

RCC has a current output of 6 million metric tonnes of cement, slated to increase to 10 million by 2022, and later to 22 million tonnes. Mr. Ghose said the COVID-19 pandemic has thrown a major challenge to the business, but RCC was facing it successfully with no change in leadership or vision.

Recently, RCC had won certifications from other parts of the world, boosting its export scope. These are from BIS (Bureau of Indian Standards), enabling it to stabilize its presence in India, and from SABPS (South African All Brothers Products and Systems) to help RCC leverage the South African market.

Mr. Salim bin Ahmed bin Alawi Al Ibrahim, Acting Deputy Group CEO of RCC said: “The cement now produced at RCC’s Salalah plant has accomplished the strictest environmental criterion of Hexavalent Chromium (Cr6+) content of less than two parts per million. The NF certification also opens up new market opportunities and we are now introducing a superior quality cement brand to the French colonies in the Indian Ocean Reunion Islands.”

Last year RCC won the ‘CEO of the Year’ honour for its Group CEO Mr. Joey Ghose, at both the Oman Best Employer Awards and GCC Best Employer Awards from Employer Branding Institute, which reinforced the company’s excellence across leadership, health and safety, technology, training and talent management.

“We regularly train our employees through on-the-job and by sending them overseas to upgrade their skills. This training helps us strictly implement quality, environmental and safety norms at our production facilities to improve our products in line with global demand,” added Mr. Al Ibrahim.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye